News
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: M1 Kliniken AG Acquires Online Pharmacy and Secures Long-Term Procurement Advantages
EQS-News: Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
EQS-News: MPH Health Care AG: Q3-Zahlen 2023 Eigenkapital (Net Asset Value) steigt gegenüber dem Vorjahreszeitraum um über 58 % auf 215,7 Mio. Euro per 30. September 2023.
EQS-News: First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Relief Therapeutics Announces CEO Transition
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the
Premier, Inc. to Participate in Piper Sandler Healthcare Conference on November 29, 2023
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Piper
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
EQS-News: Eckert & Ziegler: Personnel Changes in the Management. Changes in the Executive Board and Supervisory Board.
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax announces the resumption of its liquidity contract
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
Agilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.69 billion for the fourth quarter ended Oct. 31, 2023, a decline of 8.7% reported and 9.7% core(1) compared to the fourth quarter of
EQS-News: Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy
NanoString Comments on Delaware District Court Verdict
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S
Agilent to Present at the Evercore ISI HealthCONx Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment